RESEARCH & DEVELOPMENT
New Pharmacological Targets and Biomarkers for the Treatment of Tuberculosis (TB) Two decades of rigorous study and a unifying omics strategy to TB treatment. We are now confronted with several uncertainties as well as the unfathomable implications of multi-drug resistance. Outstanding prospective leads have emerged in recent years as a result of collaborative efforts. This includes academic research, pharmaceutical corporations, government programs, and non-profit organizations. Novel biomarkers have been identified as possible medication targets by new drug development pipelines that use machine learning methodologies. Vidya Niranjan Professor and Head of the Department, Department of Biotechnology Lead- Centre of Excellence Computational Genomics, R V College of Engineering
M
ycobacterium tuberculosis (MTB), which has harmed people for more than 10 decades, is the cause of the chronic lung infectious disease known as pulmonary tuberculosis (TB). Modern chemotherapy has been crucial in the fight against TB, but the spread of HIV and the rise of drug-resistant TB pose a threat to its control. The success rate of the 6-month conventional treatment for developing TB is only 85%, despite the fact that the cure rate of TB has dramatically increased since the deployment of direct treatment short-course chemotherapy (DOTS), which was approved by the WHO. The main disadvantage of the present chemotherapy is how long it takes to complete—up to two years for drug-resistant TB (DR-TB) and 6–9 months for drug–susceptible TB (DS– TB) patients. Patient nonadherence, treatment failure, and resurgence are frequently the results of this. According to 2017 WHO Global TB Report, there were 1.67 million deaths,
34
P H AR M A F O C U S E U R O PE
ISSUE 01 - 2022
